{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021886","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.796260+00:00","generated_at":"2026-06-22T08:47:39.589674+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptive Biotechnologies Q3 revenue $47.8M (+21% YoY); narrows FY2022 revenue guidance to $185-190M","bullets":["Q3 2022 revenue $47.8M vs $39.5M in Q3 2021 (+21%); clonoSEQ test volume up 52% YoY.","Immune Medicine revenue $27.9M (+18% YoY); MRD revenue $20.0M (+26% YoY).","Net loss improved to $45.3M from $56.0M; adjusted EBITDA loss $25.9M vs $41.1M.","FY2022 revenue guidance narrowed to $185-190M from $185-195M; opex now expected below $400M.","Signed $250M non-dilutive royalty financing with OrbiMed; Epic partnership for clonoSEQ EMR integration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021886","json":"https://secwatch.observer/filing/0000950170-22-021886.json","markdown":"https://secwatch.observer/filing/0000950170-22-021886.md","text":"https://secwatch.observer/filing/0000950170-22-021886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/0000950170-22-021886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/adpt-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:47:39.589674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59d10ae8a0cd15dbaee3c358222ecb235f02e455","claim":"Adaptive Biotechnologies Corp updated its the quarter ended September 30, 2022 guidance (reaffirmed).","evidence_excerpt":"On November 3, 2022, Adaptive Biotechnologies Corporation (the “ Company ”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/0000950170-22-021886-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}